- SKYRIZI® is an interleukin-23 (IL-23)
inhibitor used for the treatment of moderate to severe
psoriasis.1
- In clinical studies, SKYRIZI®
significantly improved levels of skin clearance after just 16
weeks and maintained clearance at one year (52
weeks).1
- Non-Insured Health Benefits program lists
SKYRIZI® on its formulary effective
February 21, 2020.
- Manitoba lists
SKYRIZI® on its provincial formulary
effective March 02, 2020.
- SKYRIZI® is the only IL-23 inhibitor to
arrive at a positive conclusion with the pCPA and is currently
listed on the formularies of Alberta, Saskatchewan, Manitoba, Ontario, Quebec, Nova
Scotia and the Non-Insured Health Benefits program.
MONTRÉAL, March 11, 2020 /CNW/ -
AbbVie (NYSE: ABBV), a global, research and development-based
biopharmaceutical company, announced today that SKYRIZI®
(risankizumab) is now listed on the formularies of the Non-Insured
Health Benefits program (NIHB) and the province of Manitoba for the treatment of moderate to
severe plaque psoriasis. This announcement comes just three months
after AbbVie successfully reached an agreement with the
pan-Canadian Pharmaceutical Alliance (pCPA), bringing a much-needed
treatment to patients living with psoriasis.
Psoriasis is a chronic condition affecting 125 million people
worldwide, including 1 million Canadians, and many patients despite
treatment still do not reach their goals or lose treatment response
over time.2-4 The most common form is plaque
psoriasis, which affects approximately 90% of patients.
5
SKYRIZI® (risankizumab) is part of a collaboration
between Boehringer Ingelheim and AbbVie, with AbbVie leading
development and commercialization globally.
"It's been very rewarding to see my psoriasis patients on the
biologic SKYRIZI® respond so favorably. In my patients,
I witness both a durable skin response and an improvement in
quality of life and well-being," states Dr. Marni C. Wiseman MD FRCPC, Dermatologist from
SKiNWISE DERMATOLOGY. "There currently is a need for treatments
with longer dosing intervals for patients located in remote
communities. I am so pleased that Manitobans and Canada's Indigenous population will have
better access to this treatment," adds Dr. Wiseman.
According to the 2016 census, Aboriginal peoples in Canada totaled 1,673,785 people, or 4.9% of
the national population.6 Of these, 223,310 Aboriginal
people live in Manitoba, making up
18.0% of that population.7
For the Non-Insured Health Benefits program (NIHB),
SKYRIZI® is effectively listed on NIHB's Limited Use
formulary as of February 21, 2020 and
criteria details will be featured in their next bulletin
update.
Information regarding the Manitoba provincial criteria may be found by
consulting the following link:
- Manitoba Drug Benefits and Interchangeability Formulary
About
SKYRIZI®
SKYRIZI® is a
novel, humanized immunoglobulin monoclonal antibody designed to
selectively inhibit IL-23, a naturally occurring cytokine involved
in inflammatory and immune responses.1 On
April 17, 2019, SKYRIZI™ received a
NOC from Health Canada for the treatment of moderate to severe
plaque psoriasis in patients who are candidates for systemic
therapy or phototherapy, based on results from clinical studies
showing significant improvement in levels of skin clearance after
just 16 weeks and at 52 weeks with every 3-month dosing in more
than 2000 adult patients.1 Four pivotal Phase 3 studies,
ultIMMa-1, ultIMMa-2, IMMvent and IMMhance evaluated more than
2,000 patients with moderate to severe plaque
psoriasis.4 Canadians living with moderate to severe
plaque psoriasis were well represented in all four of the pivotal
clinical trials leading to Health Canada's approval, showing the
Canadian leadership in this clinical development program.
About AbbVie Care
The AbbVie Care program is designed
to provide a wide range of customized services including
reimbursement and financial support, pharmacy services, lab work
reminders and coordination, personalized education and ongoing
disease management support throughout the treatment
journey. For more information, consult www.abbviecare.ca.
About AbbVie
AbbVie is a global, research and
development-based biopharmaceutical company committed to
developing innovative advanced therapies for some of the world's
most complex and critical conditions. The company's mission is to
use its expertise, dedicated people and unique approach to
innovation to markedly improve treatments across four primary
therapeutic areas: immunology, oncology, virology and neuroscience.
In more than 75 countries, AbbVie employees are working every day
to advance health solutions for people around the world. For more
information about AbbVie, please visit us
at www.abbvie.ca and www.abbvie.com. Follow
@abbvieCanada and @abbvie on Twitter or view careers on
our Facebook or LinkedIn page.
References:
1.
|
SKYRIZI® (risankizumab) [Canadian
Product Monograph]. AbbVie Corporation, April 17,
2019.
|
2.
|
International
Federation of Psoriasis Associations. Accessed March 22, 2019.
Available
at: https://ifpa-pso.com/wp-content/uploads/2017/01/Brochure-Psoriasis-is-a-serious-disease-deserving-global-attention.pdf.
|
3.
|
Mroweitz, U., et al.
Definition of treatment goals for moderate to severe psoriasis: a
European consensus. Arch Dermatol Res. 2011 Jan; 303(1):
1–10.
|
4.
|
Levin, et al.
Biologic fatigue in psoriasis. J Dermatolog Treat. 2014
Feb;25(1):78-82. doi: 10.3109/09546634.2013.826341.
|
5.
|
Canadian Dermatology
Association – Psoriasis. Accessed on February 5,
2020.
|
6.
|
Statistics Canada,
Aboriginal Population Profile, 2016 Census.
|
7.
|
Statistics Canada,
Focus on Geography Series, Province of Manitoba, 2016
Census.
|
SOURCE AbbVie